TY - JOUR T1 - Short-term results of a registered smoking cessation clinic with patients referred by ALO 171 Quitline JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P4160 AU - Dorina Rama Esendagli AU - Ozge Ozturk AU - Derya Ersel AU - Seha Akduman AU - Deniz Koksal AU - Salih Emri Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P4160.abstract N2 - According to the Global Adult Tobacco Survey 2012 in Turkey overall smoking rate is 27.1%. Within the MPOWER package, one of the main issues is to offer help by referring smokers to registered smoking cessation clinics. Here, the results of a follow up of patients with tobacco addiction referred from the ALO 171 official quitline of Ministry of Health are presented. This smoking cessation clinic is functional for over 1 year.Each patient underwent a survey asking demographic information, motivation to quit, Fagerstrom test (FT), physical examination, amount of exhaled CO, pulmonary function test, chest x-ray, and treatment given.A total of 192 patients (63% male) was followed. Mean age was 43±13 (Avg±SD). Mean packet/year consumed was 25.80±20.05 and 54% were heavy-smokers. Majority of the patients (87%) participated to a cessation program for the first time and 27.1% never tried to quit before. According to FT 43.8% of the patients were highly addicted. Yet, 69.8% were highly motivated and confident for quitting. Only 34.9% heard about the pharmacotherapy.The patients were identified with chronic cough 40.6%, sputum 43.8%, hemoptysis 2.6%, dyspnea 33.9%, angina 17.7%, diabetes 4.7%, and hypertension and high cholesterol 6.8%. The patients had exhaled CO 9.3±4.9; FEV1, 2.9±0.9L; FEV1/FVC 80.9±11.2 values.Only 44.3% of patients took the treatment correctly. Unfortunately, 45.3% who did notquit smoking had either refused or inappropriately used the treatment. Following the treatment, there was an overall quittance rate of 18.2% (varenycline 38.2%; 29.4% NRT; 26.5% bupropione, and 5.7% drugs combination). There was no significant difference between the treatment modalities. ER -